# Biotechnology
Latest news and articles about Biotechnology
Total: 46 articles found
The Silicon Apothecary: China’s AI Push to Standardize Traditional Medicine
China is leveraging artificial intelligence to modernize its multi-billion dollar Traditional Chinese Medicine industry by digitizing the sensory expertise of master herbalists. The National Modern TCM Innovation Center’s new AI tools aim to standardize quality and shift the sector toward a 'precision medicine' model.
China’s Biotech Vanguard: Breakthroughs in Lymphoma and Obesity Signal a Shift Toward Global Leadership
China is transitioning from a follower to a leader in biotech, evidenced by Lupin Pharmaceuticals' approval of the first 4th-gen BTK inhibitor and Hansoh Pharma's potent new weight-loss drug. These breakthroughs, supported by massive out-licensing deals with firms like Regeneron, demonstrate that Chinese innovation is now competitive on a global scale.
The Gilded Cage of Claude 5: Anthropic’s New Model and the Paradox of AI Safety
Anthropic has launched Claude 5, a 'Mythos-class' AI that significantly advances coding and visual autonomy but includes aggressive safety filters that downgrade the model to older versions for sensitive topics. While the model showcases 'state-of-the-art' performance, its restricted public release highlights the growing tension between AI safety and the needs of the scientific community.
The Pentagon’s Widening Net: Washington’s New List Signals the Securitization of Chinese Big Tech
The U.S. Pentagon has expanded its 1260H list of Chinese military-linked companies to 188 entities, adding major tech firms like Alibaba and Baidu. This move signifies a strategic pivot toward broad technological containment, forcing Beijing to accelerate its drive for indigenous innovation and self-reliance in critical sectors like AI and biotech.
China’s Biotech Ambitions: Shanghai Launches Elite Training to Bridge the Clinical Trial Talent Gap
Shanghai has launched a high-level training initiative to equip clinical trial Principal Investigators with the international leadership skills necessary to lead global research. The project aims to harmonize Chinese clinical standards with international benchmarks, supporting the global expansion of China's innovative drug industry.
Silicon Valley’s Swarm: Google’s Bold Bet on Biological Pest Control
Google’s life sciences arm is seeking federal approval to deploy 32 million sterile mosquitoes across California and Florida. By leveraging the Wolbachia bacterium to suppress wild populations, the project represents a significant leap in the use of biotechnology to combat mosquito-borne diseases.
Google’s Biological Gambit: Releasing 32 Million Sterile Mosquitoes to Reshape Public Health
Google’s life sciences arm is seeking approval to release 32 million sterile male mosquitoes in the U.S. to combat infectious diseases. Using the Wolbachia bacterium to induce sterility, the project aims to collapse wild mosquito populations without the use of toxic pesticides.
Asia’s Quest for Artificial Life: Shenzhen Leads Regional 10-Year Roadmap for Synthetic Cells
A Shenzhen-led team of scientists from six Asian nations has published a 10-year roadmap in Nature Biotechnology for the development of synthetic cells. The strategy aims to unify regional research in AI and bio-manufacturing to eventually engineer artificial life, signaling Asia's growing dominance in the global synthetic biology sector.
From Outsourcing to Outpacing: China’s Biotech Leap Triggers Alarm in Washington
Pfizer’s multi-billion dollar partnership with Innovent Biologics underscores China’s rapid ascent from a pharmaceutical follower to a global innovation hub. As Chinese firms begin to outperform Western incumbents in clinical trials and regulatory speed, Washington is increasingly viewing the biotech sector through a lens of national security and competition.
CSPC Pharma Pivots to Next-Gen Cell Therapy with mRNA-Based CAR-T Clinical Approval
CSPC Pharmaceutical Group has received Chinese regulatory approval to begin clinical trials for SYS6063, a dual-target CAR-T therapy delivered via mRNA-LNP technology. This milestone reflects a strategic shift toward non-viral delivery systems that could make advanced cancer treatments more scalable and cost-effective.
Bispecific Ambition: Akeso’s Ivonescimab Challenges the Oncology Hierarchy in Chicago
Akeso Biopharma’s ivonescimab has demonstrated a significant survival advantage over traditional PD-1 therapies in a landmark Phase III lung cancer trial. While the results signal a shift toward bispecific antibodies as the new standard, experts caution that further global data and longer follow-up are needed to solidify its dominance.
Shanghai’s Post-2025 Blueprint: Betting on the Brain-Computer Interface Frontier
Shanghai has released its 15th Five-Year Plan for the service industry, placing heavy emphasis on Brain-Computer Interfaces, precision medicine, and AI-driven healthcare. The blueprint aims to transform the city into a global leader for clinical innovation and high-tech medical services between 2026 and 2030.